NASDAQ:BLCM Bellicum Pharmaceuticals (BLCM) Stock Forecast, Price & News $0.48 +0.11 (+29.02%) (As of 09/22/2023 08:53 PM ET) Add Compare Share Share Today's Range$0.32▼$0.4850-Day Range$0.28▼$0.5652-Week Range$0.15▼$1.50Volume5,400 shsAverage Volume1.07 million shsMarket Capitalization$4.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Bellicum Pharmaceuticals (NASDAQ:BLCM) StockBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Read More BLCM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLCM Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Bellicum Pharmaceuticals (NASDAQ:BLCM)July 13, 2023 | finance.yahoo.comBLCM - Bellicum Pharmaceuticals, Inc.September 25, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 3, 2023 | fool.comBellicum Pharmaceuticals (NASDAQ: BLCM)May 8, 2023 | investorplace.comWhy Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?April 18, 2023 | msn.comWhy Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving PremarketApril 18, 2023 | benzinga.comShort Volatility Alert: Bellicum PharmaMarch 15, 2023 | msn.comBLCM Plummets on Stopping Trials of BPX-601 and BPX-603September 25, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 15, 2023 | msn.comWhy Bellicum Pharmaceuticals (BLCM) Stock Is Down 48%March 14, 2023 | finance.yahoo.comBellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic AlternativesFebruary 24, 2023 | finance.yahoo.comWhy Bellicum Pharmaceuticals Stock Is Plunging TodayFebruary 16, 2023 | finance.yahoo.comBellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers SymposiumJanuary 31, 2023 | finance.yahoo.comCORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 19, 2023 | finance.yahoo.comBellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers SymposiumNovember 13, 2022 | finanznachrichten.deBellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateNovember 10, 2022 | finance.yahoo.comBellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateOctober 4, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the MesaSeptember 15, 2022 | seekingalpha.comBLCM Bellicum Pharmaceuticals, Inc.September 1, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 25, 2022 | finance.yahoo.comBellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock NowAugust 18, 2022 | finance.yahoo.comIs Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?August 11, 2022 | finance.yahoo.comBellicum Reports Second Quarter 2022 Financial Results and Provides Operational UpdateMay 13, 2022 | seekingalpha.comBellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42May 13, 2022 | finance.yahoo.comBellicum Reports First Quarter 2022 Financial Results and Provides Operational UpdateMarch 24, 2022 | finance.yahoo.comBellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational UpdateFebruary 16, 2022 | benzinga.comLadenburg Thalmann Initiates Coverage On Bellicum Pharmaceuticals with Buy Rating, Announces Price Target of $5See More Headlines Receive BLCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BLCM Company Calendar Last Earnings8/10/2023Today9/24/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLCM CUSIPN/A CIK1358403 Webwww.bellicum.com Phone(281) 454-3424FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,970,000.00 Net MarginsN/A Pretax Margin-1,922.27% Return on Equity-753.35% Return on Assets-142.22% Debt Debt-to-Equity RatioN/A Current Ratio2.50 Quick Ratio2.50 Sales & Book Value Annual Sales$1.50 million Price / Sales3.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book2.09Miscellaneous Outstanding Shares9,500,000Free Float8,518,000Market Cap$4.56 million OptionableOptionable Beta1.40 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Charles S. Grass (Age 63)Principal Accounting Officer Mr. Joseph Senesac (Age 53)Sr. VP of Technical Operations & Quality Dr. Alan K. Smith Ph.D. (Age 65)Chief Scientific Officer Comp: $536.43kKey CompetitorsEvoke PharmaNASDAQ:EVOKAgile TherapeuticsNASDAQ:AGRXDermata TherapeuticsNASDAQ:DRMACyclacel PharmaceuticalsNASDAQ:CYCCObsEvaNASDAQ:OBSVView All CompetitorsInstitutional OwnershipBoxer Capital LLCBought 450,000 shares on 8/15/2023Ownership: 4.737%View All Institutional Transactions BLCM Stock - Frequently Asked Questions Should I buy or sell Bellicum Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares. View BLCM analyst ratings or view top-rated stocks. How have BLCM shares performed in 2023? Bellicum Pharmaceuticals' stock was trading at $0.72 on January 1st, 2023. Since then, BLCM shares have decreased by 33.4% and is now trading at $0.4797. View the best growth stocks for 2023 here. When is Bellicum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our BLCM earnings forecast. How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter. When did Bellicum Pharmaceuticals' stock split? Bellicum Pharmaceuticals's stock reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did Bellicum Pharmaceuticals IPO? (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager. What is Bellicum Pharmaceuticals' stock symbol? Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM." Who are Bellicum Pharmaceuticals' major shareholders? Bellicum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (4.74%). View institutional ownership trends. How do I buy shares of Bellicum Pharmaceuticals? Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bellicum Pharmaceuticals' stock price today? One share of BLCM stock can currently be purchased for approximately $0.48. How much money does Bellicum Pharmaceuticals make? Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $4.56 million and generates $1.50 million in revenue each year. How can I contact Bellicum Pharmaceuticals? Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for the company is www.bellicum.com. The biopharmaceutical company can be reached via phone at (281) 454-3424 or via email at robert.uhl@westwicke.com. This page (NASDAQ:BLCM) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.